# Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa

> **NCT02567279** · PHASE3 · TERMINATED · sponsor: **University Hospital, Montpellier** · enrollment: 2 (actual)

## Conditions studied

- Anorexia Nervosa

## Interventions

- **DRUG:** Denosumab subcutaneous injections
- **DRUG:** Placebo subcutaneous injections

## Key facts

- **NCT ID:** NCT02567279
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-01
- **Primary completion:** 2019-01-03
- **Final completion:** 2019-01-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Great difficulties were encountered during recruitment, for fear Denozumab. Only 2 patients have been included since the study start.
- **Last updated:** 2019-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567279, "Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02567279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*